IL300996A - Treatment method for patients with reduced sensitivity to BCL-2 inhibitor - Google Patents

Treatment method for patients with reduced sensitivity to BCL-2 inhibitor

Info

Publication number
IL300996A
IL300996A IL300996A IL30099623A IL300996A IL 300996 A IL300996 A IL 300996A IL 300996 A IL300996 A IL 300996A IL 30099623 A IL30099623 A IL 30099623A IL 300996 A IL300996 A IL 300996A
Authority
IL
Israel
Prior art keywords
antibody
certain embodiments
upregulated
binding fragment
expression level
Prior art date
Application number
IL300996A
Other languages
English (en)
Hebrew (he)
Inventor
Haard Johannes De
Anna Hultberg
Julie Jacobs
Piotr Zabrocki
Clayton Smith
Craig Jordan
Original Assignee
argenx BV
Univ Colorado Regents
Haard Johannes De
Anna Hultberg
Julie Jacobs
Piotr Zabrocki
Clayton Smith
Craig Jordan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by argenx BV, Univ Colorado Regents, Haard Johannes De, Anna Hultberg, Julie Jacobs, Piotr Zabrocki, Clayton Smith, Craig Jordan filed Critical argenx BV
Publication of IL300996A publication Critical patent/IL300996A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A61K31/708Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid having oxo groups directly attached to the purine ring system, e.g. guanosine, guanylic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57505Immunoassay; Biospecific binding assay; Materials therefor for cancer of the blood, e.g. leukaemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70575NGF/TNF-superfamily, e.g. CD70, CD95L, CD153 or CD154
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/52Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00Detection or diagnosis of diseases
    • G01N2800/70Mechanisms involved in disease identification
    • G01N2800/7023(Hyper)proliferation
    • G01N2800/7028Cancer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
IL300996A 2020-08-29 2021-08-27 Treatment method for patients with reduced sensitivity to BCL-2 inhibitor IL300996A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063072113P 2020-08-29 2020-08-29
PCT/EP2021/073816 WO2022043538A1 (en) 2020-08-29 2021-08-27 Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor

Publications (1)

Publication Number Publication Date
IL300996A true IL300996A (en) 2023-04-01

Family

ID=77821706

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300996A IL300996A (en) 2020-08-29 2021-08-27 Treatment method for patients with reduced sensitivity to BCL-2 inhibitor

Country Status (10)

Country Link
US (1) US20240182590A1 (enExample)
EP (1) EP4204098A1 (enExample)
JP (1) JP2023539493A (enExample)
KR (1) KR20230061421A (enExample)
CN (1) CN116249519A (enExample)
AU (1) AU2021334165A1 (enExample)
CA (1) CA3188634A1 (enExample)
IL (1) IL300996A (enExample)
MX (1) MX2023002318A (enExample)
WO (1) WO2022043538A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201800649D0 (en) 2018-01-16 2018-02-28 Argenx Bvba CD70 Combination Therapy
AU2019265019B2 (en) 2018-05-11 2025-11-06 Beam Therapeutics Inc. Methods of substituting pathogenic amino acids using programmable base editor systems
AU2023390486A1 (en) * 2022-12-08 2025-07-03 The Regents Of The University Of Colorado, A Body Corporate Methods for identifying resistance or response to venetoclax/hypomethylating agent/anti-cd70 agent treatment for acute myeloid leukemia

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1594542T3 (da) 2003-02-20 2010-10-11 Seattle Genetics Inc Anti-CD70 antistof-lægemiddelkonjugater og deres anvendelse ved behandling af cancer
US20080025989A1 (en) * 2003-02-20 2008-01-31 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
AU2007333098A1 (en) 2006-12-14 2008-06-19 Medarex, Inc. Human antibodies that bind CD70 and uses thereof
US8546399B2 (en) 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
KR101923364B1 (ko) 2010-11-23 2018-11-30 애브비 인코포레이티드 아폽토시스­유도제의 염 및 결정형
US10391168B1 (en) * 2014-08-22 2019-08-27 University Of Bern Anti-CD70 combination therapy
US11001582B2 (en) 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
WO2017212431A1 (en) 2016-06-09 2017-12-14 Dr. Reddy’S Laboratories Limited Solid forms of venetoclax and processes for the preparation of venetoclax
EP3481397A1 (en) 2016-07-06 2019-05-15 Concert Pharmaceuticals Inc. Deuterated venetoclax
CN107648185A (zh) 2016-07-25 2018-02-02 常州爱诺新睿医药技术有限公司 一种无定型Venetoclax与药用辅料的固体分散体及其制备方法
WO2018029711A2 (en) 2016-08-12 2018-02-15 Mylan Laboratories Limited Process for the preparation of venetoclax
US10800777B2 (en) 2016-10-14 2020-10-13 Mylan Laboratories Limited Polymorphic forms of VENCLEXTA
EP3333167A1 (en) 2016-12-09 2018-06-13 LEK Pharmaceuticals d.d. Solid forms of venetoclax
WO2018157803A1 (zh) 2017-02-28 2018-09-07 苏州科睿思制药有限公司 维奈妥拉的晶型及其制备方法
WO2018167652A1 (en) 2017-03-13 2018-09-20 Laurus Labs Limited Process for preparation of amorphous form of venetoclax
CN107089981A (zh) 2017-04-24 2017-08-25 杭州科耀医药科技有限公司 一种BCL‑2抑制剂Venetoclax的合成方法
GB2567613A (en) 2017-06-16 2019-04-24 Argenx Bvba Treatment for acute myeloid leukaemia
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Cd70組合治療

Also Published As

Publication number Publication date
AU2021334165A8 (en) 2023-03-16
KR20230061421A (ko) 2023-05-08
JP2023539493A (ja) 2023-09-14
AU2021334165A1 (en) 2023-03-02
CA3188634A1 (en) 2022-03-03
WO2022043538A1 (en) 2022-03-03
EP4204098A1 (en) 2023-07-05
US20240182590A1 (en) 2024-06-06
MX2023002318A (es) 2023-05-19
CN116249519A (zh) 2023-06-09

Similar Documents

Publication Publication Date Title
US20250152707A1 (en) Cd70 combination therapy
US20240182590A1 (en) Method of treatment of patients having reduced sensitivity to a bcl-2 inhibitor
CN106459184B (zh) 与抗cd38抗体联用的组合疗法
JP7498564B2 (ja) 急性骨髄性白血病治療のための抗-cd70抗体argx-110の使用
WO2019189780A1 (ja) 癌の治療及び/又は予防用医薬組成物
KR20220103959A (ko) 신규한 항-cd47 항체 및 그 용도
EA050897B1 (ru) Способ лечения пациентов с пониженной чувствительностью к ингибитору bcl-2
HK40089820A (zh) 治疗对bcl-2抑制剂具有降低的敏感性的患者的方法
CA3117282C (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40097470A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40091007A (zh) 用於治疗急性骨髓性白血病的cd70 和bcl-2 抑制剂的组合疗法
HK40091007B (zh) 用於治疗急性骨髓性白血病的cd70 和bcl-2 抑制剂的组合疗法
HK40052961A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40052961B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
WO2020119792A1 (en) Humanized antibodies against ox40, method for preparing the same, and use thereof
EA049354B1 (ru) Cd70 и венетоклакс, ингибитор bcl-2, комбинированная терапия для лечения острого миелоидного лейкоза
HK40049607B (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
HK40049607A (en) Cd70 and venetoclax, a bcl-2 inhibitor, combination therapy for treating acute myeloid leukemia
BR122024010998A2 (pt) Uso de um anticorpo anti-cd38